Alexion Pharmaceuticals, Inc. (ALXN) Tops Q1 EPS by 27c

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) reported Q1 EPS of $1.53, $0.27 better than the analyst estimate of $1.26. Revenue for the quarter came in at $566.6 million versus the consensus estimate of $560.22 million.

Alexion Pharmaceuticals, Inc. sees FY2014 EPS of $4.75-$4.85, versus prior guidance of $4.37-$4.47 and the consensus of $4.49.

For earnings history and earnings-related data on Alexion Pharmaceuticals, Inc. (ALXN) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• VNET Group (VNET) Misses Q2 EPS by 164c
• Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance